ITMCTR1900002409招募中未知
Study for protein expression of the complement activation product C4a in patient plasma of non-small cell lung cancer of different clinical stages
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Basic Science
入排标准
- 年龄范围
- 30 至 80（—）
- 性别
- All
入选标准
- •1 Inclusion criteria of patients with non-small cell lung cancer:
- •(1) Participants who are dignosed as stage I or IV non-small cell lung cancer by pathological or cytological methods;
- •(2) Aged 30~80;
- •(3) ECOG score: 0-3, KPS=50;
- •(4) Participants have signed informed consent and have good compliance.
- •2. Inclusion criteria of non-cancer controls:
- •(1) Participants who are not diagnosed as cancer;
- •(2) Aged 30~80 years;
- •(3) Participants have signed informed consent.
排除标准
- •1. Exclusion criteria of patients with non-small cell lung cancer:
- •(1) Participants who have received immunoenhancer or immunosuppressant half a month before sampling;
- •(2) Participants who have received radiotherapy and chemotherapy half a month before sampling;
- •(3) Participants who are diagnosed as severe recurrent diseases (such as autoimmune diseases and leukemia);
- •(4) Participants who are diagnosed as microbial (including bacterial, viral and mycoplasma infection) infection;
- •(5) Participants who have received blood transfusion one year before sampling.
- •2. Exclusion criteria of non-cancer controls:
- •(1) Participants who are diagnosed as severe recurrent diseases (such as autoimmune diseases and leukemia);
- •(2) Participants who are diagnosed as microbial (including bacterial, viral and mycoplasma infection) infection;
- •(3) Participants who received blood transfusion one year before sampling.
研究者
相似试验
招募中
不适用
Investigation of complement activation and autoantibody formation in lysosomal storage diseases: Fabry disease and Gaucher's diseaseGaucher's diseaseFabry diseaseE75.2Other sphingolipidosisDRKS00022211eleva GmbH150
尚未招募
不适用
Identification of complement inhibitors and complement regulatory proteins in ABO-incompatible compare with HLA-incompatible kidney transplantatioABOi kidney transplantationHLAi kidney transplantationAccommodationABO incompatibility or ABO incompatible kidney transplantationComplement regulatory proteinsComplement inhibitorsHLA incompatibility or HLA incompatible kidney transplantationKidney transplantationTCTR20210904002/A30
已完成
不适用
Investigation of complement activity between generic drug and barand-name drug for the use of anticoagulant during blood apheresis therapySepsisJPRN-UMIN000029038Shiga University of Medical Science50
已完成
不适用
SCONE Study Studies on Complement regulation in atypical hemolytic uremic syndrome following hemodialysis, plasmapheresis and treatment with Eculizumab100383601002766510038430HUShemolytic uremic syndromeNL-OMON37013niversitair Medisch Centrum16
已完成
不适用
Determination of complement binding HLA-C antibodies with single-antigen-expressing cell lines (SAL) in pregnancies complicated by preeclampsiaNL-OMON38539eids Universitair Medisch Centrum132